Drugs / MM-310
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03076372 | Feb 2017 → Jun 2018 | endometrial carcinoma, gastric carcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma +7 | Merrimack Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MM-310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03076372 ↗ |
| Route | Intravenous | “MM-310 will be administered by IV infusion over 90 minutes” NCT03076372 ↗ |
| Target | EPHA2 | “targets the EphA2 receptor on cancer cells” NCT03076372 ↗ |